



Diagnostic Laboratory Services, Inc

Antimicrobial Susceptibility Profile (Jan 2010 – June 30, 2010)

CARE FACILITIES - ALL SOURCES

GRAM NEGATIVE SUSCEPTIBILITIES (Percent Susceptible)

	Enterobacter aerogenes	Enterobacter cloacae	E. coli	E. coli ESBL	Kleb pneumoniae	K. pneumo ESBL	Pseudo aeruginosa	Serratia marcescens
	Jan-Jun	Jan-Jun	Jan-Jun	Jan-Jun	Jan-Jun	Jan-Jun	Jan-Jun	Jan-Jun
Amikacin	100	100	100	100	100	n/a	100	100
Amoxicillin/CA	0	0	87		96			0
Ampicillin			50					
Cefazolin	0	0	90		84			0
Cefepime	100	100	99		100		93	100
Cefoxitin	0	0	90	55	96	n/a		33
Ceftriaxone	100	100	99		100		3	100
Ciprofloxacin	100	50	57	4	100	n/a	63	100
Gentamicin	100	100	86	66	100	n/a	86	100
Levofloxacin							50	
Nitrofurantoin (u)	0	25	97	89	8	n/a		0
Pip/Tazobactam	100	100	99	93	84	n/a	93	100
Tigecycline	100	100	100	100	96	n/a		100
Tobramycin	100	100	94	74	100	n/a	100	100
Trimeth-Sulfa	100	25	76	37	74	n/a		100
<b>Total Isolates</b>	1 ***	4 ***	74	27	25	0	29	3 ***

GRAM POSITIVE AND *H. influenzae* SUSCEPTIBILITIES (Percent Susceptible)

	S.aureus MRSA	S.aureus MSSA	Staph coag neg	Enterococcus	Strep pneumo	Haemophilus influenza
	Jan-Jun	Jan-Jun	Jan-Jun	Jan-Jun	Jan-Jun	Jan-Jun
Ampicillin				67		n/a
Cefazolin	0	100	46			
Ceftriaxone *					38	n/a
Cefuroxime						n/a
Chloramphenicol						n/a
Ciprofloxacin	4	50	15	41		
Clindamycin	23	57	54			
Erythromycin	11	36	54		0	
Gentamicin	93	100	100			
Linezolid	100	100	100	96		
Meropenem						n/a
Moxifloxacin	4	50	15		25	n/a
Nitrofurantoin (u)	100	100	85	75		
Oxacillin	0	100	46			
Penicillin	0	21	7		0	
Rifampin **	100	100	100			
Tetracycline	92	79	92	25	100	n/a
Trimeth-Sulfa	96	100	54		0	n/a
Vancomycin	100	100	100	96	100	
<b>Total Isolates</b>	26	14	13	24	4 ***	0

\* Ceftriaxone (Strep pneumoniae) percentage based on non-meningitis interpretation.

\*\* Rifampin should not be used alone for treatment of staph infection.

\*\*\* Note: For total isolate less than 10, the susceptibility percentage may not be clinically significant.